5-(N,N-dimethyl)-Amiloride (hydrochloride): Benchmark NHE1 Inhibitor for Intracellular pH and Cardiovascular Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA, SKU C3505, APExBIO) is a crystalline, cell-permeable compound that selectively inhibits Na⁺/H⁺ exchanger isoforms NHE1, NHE2, and NHE3 (K_i = 0.02, 0.25, and 14 µM, respectively) while sparing NHE4, NHE5, and NHE7, thereby enabling precise modulation of intracellular pH in mammalian cells (APExBIO product page). DMA demonstrates protective effects in preclinical models of ischemia-reperfusion injury by normalizing sodium levels and contractility in cardiac tissue (Chen et al., 2021). The compound also inhibits ouabain-sensitive ATPase activity and alanine uptake in hepatocytes, extending its utility to broader ion transport and metabolic studies. Due to its high aqueous solubility (up to 30 mg/ml in DMSO/DMF) and rapid mechanism, DMA is well-suited for in vitro and ex vivo research applications. This article details the biological rationale, mechanism, evidence, and practical integration of DMA, with direct contrasts to related literature and guidance on avoiding common misconceptions.

Biological Rationale

The Na⁺/H⁺ exchangers (NHEs) are integral membrane proteins that regulate intracellular pH and cell volume by exchanging intracellular H⁺ for extracellular Na⁺ ions in mammalian cells. NHE1 is the most ubiquitously expressed isoform and is essential for maintaining cytosolic pH homeostasis, cell survival, and migration (Chen et al., 2021). Dysregulation of NHE1 signaling is linked to cardiovascular diseases, ischemia-reperfusion injury, and increased endothelial permeability observed in sepsis and inflammation. Pharmacological inhibition of NHE1, NHE2, and NHE3 provides a precise approach to dissecting their roles in cellular physiology and disease. 5-(N,N-dimethyl)-Amiloride (hydrochloride), developed by APExBIO, is a validated tool for selective NHE inhibition and investigation of these signaling pathways (Related review).

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a structural analog of amiloride with dimethylation at the 5-position, substantially increasing its potency and selectivity for NHE1. DMA acts as a competitive inhibitor, binding to the extracellular domain of NHE1 and related isoforms, thereby blocking the exchange of Na⁺ and H⁺ across the plasma membrane. The reported inhibition constants (K_i) are 0.02 µM for NHE1, 0.25 µM for NHE2, and 14 µM for NHE3, indicating >100-fold selectivity for NHE1 over NHE3 (APExBIO). DMA has negligible effect on NHE4, NHE5, and NHE7 at comparable concentrations, enabling isoform-specific studies (Proteinabeads review—this article expands by integrating new ischemia-reperfusion data).

By inhibiting NHE1, DMA prevents cellular proton extrusion and sodium entry, leading to intracellular acidification and reduced sodium accumulation. This action disrupts downstream signaling events, including regulation of cytoskeletal dynamics, contractile function, and cell survival pathways. DMA also inhibits ouabain-sensitive ATPase activity in rat liver plasma membranes and reduces alanine uptake in hepatocytes, supporting its broader effects on ion transport and metabolism (APExBIO).

Evidence & Benchmarks

• DMA inhibits NHE1 with a K_i of 0.02 µM under physiological conditions (pH 7.4, 37°C) (APExBIO).
• DMA provides >100-fold selectivity for NHE1 over NHE3, with minimal off-target activity, as confirmed in isoform-specific transport assays (Proteinabeads, 2023).
• In ex vivo cardiac models, DMA administration reduces tissue sodium load and preserves contractile function after ischemia-reperfusion (30 min ischemia, 60 min reperfusion) (Chen et al., 2021).
• DMA inhibits ouabain-sensitive ATP hydrolysis (IC₅₀ ~10 µM) and sodium-potassium ATPase activity in rat liver plasma membranes (APExBIO).
• Alanine uptake into hepatocytes is reduced by DMA at ≥10 µM, indicating disruption of coupled sodium transport pathways (Doripenemhydrate review—this article provides mechanistic context).

Applications, Limits & Misconceptions

DMA is primarily used in:

• Elucidating the role of NHE1 in intracellular pH regulation, cell viability, and migration (Ionomycin review; here, we extend to metabolic regulation and ischemia models).
• Modeling ischemia-reperfusion injury in cardiac and endothelial tissues.
• Dissecting Na⁺/H⁺ exchanger signaling in sepsis and vascular permeability research (Aclacinomycina review; this article updates with new selectivity data and application guidance).
• Optimizing cell-based assays for cytotoxicity, viability, and proliferation (DNTP-mix review; we clarify recommended storage and workflow integration here).

Common Pitfalls or Misconceptions

• DMA is not suitable for long-term solution storage; prepared solutions should be used promptly due to instability at room temperature (APExBIO).
• DMA does not significantly inhibit NHE4, NHE5, or NHE7; use alternative inhibitors for these isoforms (Proteinabeads, 2023).
• DMA is for research use only; it is not approved for diagnostic or therapeutic purposes (APExBIO).
• DMA may interfere with other sodium-dependent transporters at higher concentrations; titrate dose carefully to maintain selectivity (Doripenemhydrate review).
• Not all cell types respond identically; verify NHE expression profile in your model before use.

Workflow Integration & Parameters

DMA is soluble up to 30 mg/ml in DMSO or DMF. For cell-based assays, a typical working concentration ranges from 0.1 to 10 µM, diluted in physiological buffer (pH 7.2–7.4). Solutions should be freshly prepared and used within 2–3 hours. Store DMA powder at -20°C; avoid repeated freeze-thaw cycles. For studies targeting NHE1, use concentrations ≤1 µM to maximize selectivity. In metabolic or ATPase assays, titrate DMA to assess off-target effects. For endothelial permeability or ischemia-reperfusion models, follow established protocols for timing and dose (e.g., pretreatment 10–30 min prior to hypoxic insult) (APExBIO).

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) remains a gold-standard tool for dissecting Na⁺/H⁺ exchanger function in cardiovascular, metabolic, and cell signaling research. Its potency, selectivity, and versatility underpin its adoption in both basic and translational workflows. Future research may further clarify its roles in emerging models of vascular permeability and sepsis. For full technical details or to source validated material, visit the APExBIO product page for C3505.